Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Non-Current Deferred Tax Liability (2018 - 2024)

Historic Non-Current Deferred Tax Liability for Innate Pharma (IPHYF) over the last 7 years, with Q2 2024 value amounting to $9.8 million.

  • Innate Pharma's Non-Current Deferred Tax Liability fell 673.81% to $9.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $9.8 million, marking a year-over-year decrease of 673.81%. This contributed to the annual value of $9.7 million for FY2023, which is 1084.98% up from last year.
  • Latest data reveals that Innate Pharma reported Non-Current Deferred Tax Liability of $9.8 million as of Q2 2024, which was down 673.81% from $9.7 million recorded in Q4 2023.
  • In the past 5 years, Innate Pharma's Non-Current Deferred Tax Liability ranged from a high of $1.3 billion in Q2 2020 and a low of $5.8 million during Q4 2021
  • Its 5-year average for Non-Current Deferred Tax Liability is $148.5 million, with a median of $8.7 million in 2022.
  • Per our database at Business Quant, Innate Pharma's Non-Current Deferred Tax Liability soared by 49360.8% in 2020 and then crashed by 9948.75% in 2021.
  • Innate Pharma's Non-Current Deferred Tax Liability (Quarter) stood at $8.4 million in 2020, then tumbled by 31.93% to $5.8 million in 2021, then soared by 51.98% to $8.7 million in 2022, then increased by 10.85% to $9.7 million in 2023, then grew by 1.39% to $9.8 million in 2024.
  • Its Non-Current Deferred Tax Liability was $9.8 million in Q2 2024, compared to $9.7 million in Q4 2023 and $10.5 million in Q2 2023.